Carregant...
CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies
SIMPLE SUMMARY: CD123 is overexpressed in multiple hematologic malignancies. Advances in CD123-targeted therapies over the past decade have positioned this molecule as an integral biomarker in current practice. This review provides an overview of CD123 biology and in-depth discussion of clinical lab...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7690688/ https://ncbi.nlm.nih.gov/pubmed/33113953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113087 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|